Poxel S.A. PXXLF
0.22 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
0.70 Day range 0.70
0.22 52-week range 0.70
- YTD
- -12.00%
- 1 year
- -12.00%
News
businesswire.com Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships LYON, France--(BUSINESS WIRE)--Regulatory News: Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief…
businesswire.com Poxel Reports First Quarter 2026 Revenue and Provides a Business Update LYON, France--(BUSINESS WIRE)--Regulatory News: Poxel (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for severe chronic diseases with…
businesswire.com Poxel: Postponement of the Publication of the 2025 Annual Financial Statements and the Annual Financial Report LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company that leverages its expertise to develop innovative treatments for metabolic…
businesswire.com Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases…
businesswire.com Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic…
businesswire.com Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
businesswire.com Poxel Announces the Implementation of an Equity Line With IRIS Capital as Part of the Execution of the Recovery Plan LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
businesswire.com POXEL SA: The Commercial Court of Lyon Approves the Recovery Plan and Brings an End to the Judicial Reorganisation Proceedings LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
businesswire.com Poxel Publishes Its Financial Results for the First Half of 2025 LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases…
businesswire.com POXEL SA: Update on the Proposed Recovery Plan and Organisation of a Webinar LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases…
businesswire.com Poxel Reports Revenue for the Third Quarter 2025 LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
businesswire.com Appointment of Yves Decadt as Member of Poxel's Board of Directors LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
businesswire.com Poxel Reports Financial Results for Full Year 2024 and Provides Operational and Financial Update LYON, France--(BUSINESS WIRE)--Regulatory News: Poxel (Paris:POXEL): Webinar in French today at 6:00 p.m. (Paris time): To register for the webinar: click on this link. A presentation will be…
businesswire.com Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
businesswire.com Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
businesswire.com Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
businesswire.com Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
businesswire.com Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025 LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
businesswire.com Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
businesswire.com Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases…
benzinga.com Stocks That Hit 52-Week Highs On Friday